摘要
1例59岁男性肺鳞癌患者接受化疗联合替雷利珠单抗(200 mg静脉滴注、第1天,21 d为1个周期)治疗。间断治疗12个周期后第10天,患者全身皮肤出现红疹,局部出现水疱,部分破溃,以四肢末端为著。诊断为重症多形性红斑,考虑与替雷利珠单抗有关。停止化疗、停用替雷利珠单抗,予甲泼尼龙80 mg静脉滴注、1次/d,皮损处外敷乳膏等对症治疗。14 d后皮肤红疹明显消退,部分水疱结痂。将甲泼尼龙改为泼尼松片60 mg口服、1次/d并逐渐减量,治疗3个月余后停药。患者皮肤红疹、水疱消退,四肢皮肤破溃处有色素沉着。此后患者未再接受免疫治疗,亦未再出现皮肤不良反应。
A 59-year-old male patient with lung squamous cell carcinoma received chemotherapy combined with tislelizumab 200 mg by intravenous infusion on day 1,with 21 days as 1 cycle.On the 10th day after 12 cycles of intermittent treatments,the patient developed rashes all over the skin,with local blisters and partial ulceration,especially at the ends of the limbs.The patient was diagnosed as having erythema multiforme and considered to be related to tislelizumab.Chemotherapy was stopped and tislelizumab was discontinued.Intravenously infusion of methylprednisolone 80 mg once daily and symptomatic treatments such as topical cream to the skin lesion were given.After 14 days of treatments,the rashes were subsided obviously,and some blisters scabbed.Methylprednisolone was changed to prednisone tablets 60 mg orally once daily,which was gradually reduced until withdrawal more than 3 months later.The patient′s skin rashes and blisters were subsided,leaving pigmentation at the site of skin rupture on the limbs.Since then,the patient did not receive immunotherapy,and did not have any adverse skin reactions.
作者
张静
张新毅
Zhang Jing;Zhang Xinyi(Department of Pharmacy,Baotou Cancer Hospital,Inner Mongolia Autonomous Region,Baotou 014030,China)
出处
《药物不良反应杂志》
2025年第8期507-509,共3页
Adverse Drug Reactions Journal
基金
包头市医药卫生基金(wjwkj2020033)。
